Xiaodong Xiao

机构：AstraZeneca (Brazil), AstraZeneca (Germany) · ORCID：0009-0007-2676-450X

发表论文 72 篇 · 总被引 4658 次 · h-index 37

代表论文

• Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies (2007 · Proceedings of the National Academy of Sciences · 被引 308)
• Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens (2009 · Biochemical and Biophysical Research Communications · 被引 272)
• Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody (2006 · Journal of Biological Chemistry · 被引 266)
• Structure-Based Discovery of a Novel Angiotensin-Converting Enzyme 2 Inhibitor (2004 · Hypertension · 被引 199)
• Potent Neutralization of Hendra and Nipah Viruses by Human Monoclonal Antibodies (2005 · Journal of Virology · 被引 171)
• Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae (2017 · Nature Communications · 被引 117)